

Helen Parise

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1322413/publications.pdf>

Version: 2024-02-01

119
papers

21,498
citations

22153

59
h-index

20358

116
g-index

120
all docs

120
docs citations

120
times ranked

19717
citing authors

#	ARTICLE	IF	CITATIONS
1	Implementation of supervised exercise therapy in a veteran population with symptomatic claudication. <i>Vascular Medicine</i> , 2022, 27, 136-141.	1.5	2
2	Coronary orbital atherectomy treatment of Hispanic and Latino patients: A real-world comparative analysis. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 1752-1757.	1.7	2
3	Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). <i>Circulation</i> , 2022, 145, 1645-1654.	1.6	12
4	Off-Label Use of Balloon Mitral Valvuloplasty in Nonrheumatic Mitral Stenosis With Severe Mitral Annular Calcification. , 2022, 1, 100026.		0
5	Impact of drug adherence on blood pressure response to alcohol-mediated renal denervation. <i>Blood Pressure</i> , 2022, 31, 109-117.	1.5	2
6	A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST). <i>European Heart Journal</i> , 2021, 42, 2536-2548.	2.2	17
7	A randomized evaluation of the TriGuardâ„¢ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. <i>European Heart Journal</i> , 2021, 42, 2670-2679.	2.2	39
8	Design and rationale of the colchicine/statin for the prevention of COVID-19 complications (COLSTAT) trial. <i>Contemporary Clinical Trials</i> , 2021, 110, 106547.	1.8	4
9	Catheter-based alcohol-mediated renal denervation for the treatment of uncontrolled hypertension: design of two sham-controlled, randomized, blinded trials in the absence (TARGET BP OFF-MED) and presence (TARGET BP I) of antihypertensive medications. <i>American Heart Journal</i> , 2021, 239, 90-99.	2.7	16
10	Long-Term Results up to 12 Months After Catheter-Based Alcohol-Mediated Renal Denervation for Treatment of Resistant Hypertension. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010075.	3.9	8
11	Blood pressure lowering with alcoholâ€­mediated renal denervation using the Peregrine infusion Catheter is independent of injection site location. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E832-E838.	1.7	0
12	Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. <i>European Heart Journal</i> , 2021, 42, 4468-4477.	2.2	16
13	Evaluation of Transcatheter Alcohol-Mediated Perivascular Renal Denervation to Treat Resistant Hypertension. <i>Journal of Clinical Medicine</i> , 2020, 9, 1881.	2.4	3
14	Alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 471-484.	2.9	73
15	Safety, Performance, and Efficacy of Cardiac Contractility Modulation Delivered by the 2-Lead Optimizer Smart System. <i>Circulation: Heart Failure</i> , 2020, 13, e006512.	3.9	47
16	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. <i>JACC: Heart Failure</i> , 2018, 6, 874-883.	4.1	159
17	Prognostic utility of myocardial blush grade after PCI in patients with NSTEMIâ€­ACS: Analysis from the ACUITY trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 215-224.	1.7	6
18	Neurologic Complications of Unprotected Transcatheter Aortic Valve Implantation (from the Tj ETQq0 0 0 rgBT /Oyerlock 10 Tf 50 62 T	1.6	72

#	ARTICLE	IF	CITATIONS
19	Simplified prediction of postoperative cardiac surgery outcomes with a novel score: R 2 CHADS 2. American Heart Journal, 2016, 177, 153-159.	2.7	7
20	Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies). American Journal of Cardiology, 2016, 117, 532-538.	1.6	17
21	Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions. JACC: Cardiovascular Interventions, 2016, 9, 51-64.	2.9	67
22	Prevalence and Impact of High Platelet Reactivity in Chronic Kidney Disease. Circulation: Cardiovascular Interventions, 2015, 8, e001683.	3.9	65
23	A prospective randomized evaluation of the TriGuardâ,ç HDH embolic DEFLECTion device during transcatheter aortic valve implantation: results from the DEFLECT III trial. European Heart Journal, 2015, 36, 2070-2078.	2.2	259
24	Relationship between ST-segment resolution and anterior infarct size after primary percutaneous coronary intervention: analysis from the INFUSE-AMI trial. European Heart Journal: Acute Cardiovascular Care, 2014, 3, 78-83.	1.0	25
25	Body Mass Index and Acute and Long-Term Outcomes After Acute Myocardial Infarction (from the) Tj ETQq1 1 0.784314 rgBT /Overlock American Journal of Cardiology, 2014, 114, 9-16.	1.6	38
26	Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents. Circulation, 2014, 129, 463-470.	1.6	350
27	Prognostic Value of Angiographic Lesion Complexity in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent) Tj ETQq1 1 0.784314 rgBT /Overlock 1	1.6	38
28	Comparative effectiveness of upstream glycoprotein IIb/IIIa inhibitors in patients with moderate- and high-risk acute coronary syndromes: An Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy. American Heart Journal, 2014, 167, 43-50.	2.7	7
29	Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus. Journal of the American College of Cardiology, 2014, 63, 2111-2118.	2.8	85
30	Relation of C-Reactive Protein Levels to Instability of Untreated Vulnerable Coronary Plaques (from) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	23
31	Clinical and Angiographic Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent in Japanese Patients. Circulation Journal, 2014, 79, 96-103.	1.6	27
32	Infarct size and mortality in patients with proximal versus mid left anterior descending artery occlusion: The Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction (INFUSE-AMI) trial. American Heart Journal, 2013, 166, 64-70.	2.7	28
33	Plaque shift and distal embolism in patients with acute myocardial infarction. Catheterization and Cardiovascular Interventions, 2013, 82, 203-209.	1.7	8
34	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet, The, 2013, 382, 614-623.	13.7	740
35	Complementary prognostic utility of myocardial blush grade and ST-segment resolution after primary percutaneous coronary intervention: Analysis from the HORIZONS-AMI trial. American Heart Journal, 2013, 166, 676-683.	2.7	28
36	Dynamic Nature of Nonculprit Coronary Artery Lesion Morphology in STEMI. JACC: Cardiovascular Imaging, 2013, 6, 86-95.	5.3	53

#	ARTICLE	IF	CITATIONS
37	Relation Between White Blood Cell Count and Final Infarct Size in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50)	1.6	13
38	The REMEDEE Trial. JACC: Cardiovascular Interventions, 2013, 6, 334-343.	2.9	95
39	Relationship Between Myocardial Reperfusion, Infarct Size, and Mortality. JACC: Cardiovascular Interventions, 2013, 6, 718-724.	2.9	42
40	Objective Simulator-Based Evaluation of Carotid Artery Stenting Proficiency (from Assessment of) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Cardiology, 2013, 112, 299-306.	1.6	13
41	Long-Term Prognosis of Patients Presenting With ST-Segment Elevation Myocardial Infarction With No Significant Coronary Artery Disease (from The HORIZONS-AMI Trial). American Journal of Cardiology, 2013, 111, 643-648.	1.6	71
42	Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery. American Journal of Cardiology, 2013, 112, 753-760.	1.6	12
43	Characteristics and Outcomes of Patients With ST-Segment Elevation Myocardial Infarction Excluded from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial. American Journal of Cardiology, 2013, 111, 196-201.	1.6	10
44	Relationship Between ST-Segment Recovery and Clinical Outcomes After Primary Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2013, 6, 216-223.	3.9	39
45	Impact of Scheduled Angiographic Follow-up in Patients Treated With Primary Percutaneous Coronary Intervention for <sc>ST</sc>-segment Elevation Myocardial Infarction. Journal of Interventional Cardiology, 2013, 26, 319-324.	1.2	11
46	Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures. Thrombosis and Haemostasis, 2013, 109, 808-816.	3.4	32
47	Long-Term Follow-Up of Attenuated Plaques in Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2012, 5, 185-192.	3.9	17
48	Intracoronary Abciximab and Aspiration Thrombectomy in Patients With Large Anterior Myocardial Infarction. JAMA - Journal of the American Medical Association, 2012, 307, 1817.	7.4	471
49	Response to Letter Regarding Article, "Impact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes: The Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) Trial." Circulation, 2012, 126, .	1.6	0
50	Impact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. American Heart Journal, 2012, 163, 522-529.	2.7	71
51	Impact of the Presence and Extent of Incomplete Angiographic Revascularization After Percutaneous Coronary Intervention in Acute Coronary Syndromes. Circulation, 2012, 125, 2613-2620.	1.6	125
52	Quantification and Impact of Untreated Coronary Artery Disease After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2012, 59, 2165-2174.	2.8	310
53	Development and Validation of a Stent Thrombosis Risk Score in Patients With Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2012, 5, 1097-1105.	2.9	101
54	Safety and Efficacy of High- Versus Low-Dose Aspirin After Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction. JACC: Cardiovascular Interventions, 2012, 5, 1231-1238.	2.9	32

#	ARTICLE	IF	CITATIONS
55	Usefulness of Minimum Stent Cross Sectional Area as a Predictor of Angiographic Restenosis After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction (from the HORIZONS-AMI) Tj ETQq1 1 0.784314 49 BT /Over	1.6	49
56	Outcomes of Patients Treated With Triple Antithrombotic Therapy After Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the Harmonizing Outcomes With) Tj ETQq0 0 0 1.6 BT /Overlock 10 TF of Cardiology, 2012, 109, 831-838.	1.6	54
57	Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention, 2012, 8, 599-606.	3.2	51
58	Effect of Switching Antithrombin Agents for Primary Angioplasty in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 57, 2309-2316.	2.8	49
59	Impact of Lesion Length and Vessel Size on Clinical Outcomes After Percutaneous Coronary Intervention With Everolimus- Versus Paclitaxel-Eluting Stents. JACC: Cardiovascular Interventions, 2011, 4, 1209-1215.	2.9	115
60	A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine, 2011, 364, 226-235.	27.0	2,721
61	Rationale and design of the INFUSE-AMI study: A 2 × 2 factorial, randomized, multicenter, single-blind evaluation of intracoronary abciximab infusion and aspiration thrombectomy in patients undergoing percutaneous coronary intervention for anterior ST-segment elevation myocardial infarction. American Heart Journal, 2011, 161, 478-486.e7.	2.7	36
62	Impact of In-Hospital Major Bleeding on Late Clinical Outcomes After Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction. Journal of the American College of Cardiology, 2011, 58, 1750-1756.	2.8	127
63	Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet, The, 2011, 377, 2193-2204.	13.7	421
64	Meta-Analysis of Randomized Studies Comparing Intravascular Ultrasound Versus Angiographic Guidance of Percutaneous Coronary Intervention in Pre-Drug-Eluting Stent Era. American Journal of Cardiology, 2011, 107, 374-382.	1.6	169
65	Impact of Smoking on Outcomes of Patients With ST-Segment Elevation Myocardial Infarction (from) Tj ETQq1 1 0.784314 49 BT /Over 1.6 28	1.6	28
66	Comparison of Direct Stenting With Conventional Stent Implantation in Acute Myocardial Infarction. American Journal of Cardiology, 2011, 108, 1697-1703.	1.6	40
67	Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty. JACC: Cardiovascular Interventions, 2011, 4, 760-768.	2.9	34
68	The Relationship Between Attenuated Plaque Identified by Intravascular Ultrasound and No-Reflow After Stenting in Acute Myocardial Infarction. JACC: Cardiovascular Interventions, 2011, 4, 495-502.	2.9	99
69	Impact of Bleeding on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2011, 4, 654-664.	2.9	329
70	Frequency and Predictors of Stent Thrombosis After Percutaneous Coronary Intervention in Acute Myocardial Infarction. Circulation, 2011, 123, 1745-1756.	1.6	222
71	Intravascular Ultrasound Findings of Early Stent Thrombosis After Primary Percutaneous Intervention in Acute Myocardial Infarction. Circulation: Cardiovascular Interventions, 2011, 4, 239-247.	3.9	196
72	Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. Circulation, 2011, 124, 893-900.	1.6	188

#	ARTICLE	IF	CITATIONS
73	SYNTAX Score Reproducibility and Variability Between Interventional Cardiologists, Core Laboratory Technicians, and Quantitative Coronary Measurements. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 553-561.	3.9	140
74	Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Diabetic Patients With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Interventions</i> , 2011, 4, 130-138.	3.9	10
75	Impact of Leukocyte Count on Mortality and Bleeding in Patients With Myocardial Infarction Undergoing Primary Percutaneous Coronary Interventions. <i>Circulation</i> , 2011, 123, 2829-2837.	1.6	62
76	Strut Coverage and Late Malapposition With Paclitaxel-Eluting Stents Compared With Bare Metal Stents in Acute Myocardial Infarction. <i>Circulation</i> , 2011, 123, 274-281.	1.6	155
77	Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. <i>EuroIntervention</i> , 2011, 7, 74-83.	3.2	35
78	Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy). <i>American Journal of Cardiology</i> , 2010, 106, 180-186.	1.6	2
79	Intravascular Ultrasound Findings of Stent Fractures in Patients With Sirolimus- and Paclitaxel-Eluting Stents. <i>American Journal of Cardiology</i> , 2010, 106, 952-957.	1.6	10
80	Impact of Transfer for Primary Percutaneous Coronary Intervention on Survival and Clinical Outcomes (from the HORIZONS-AMI Trial). <i>American Journal of Cardiology</i> , 2010, 106, 1218-1224.	1.6	15
81	Predictors of Reperfusion Delay in Patients With Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention from the HORIZONS-AMI Trial. <i>American Journal of Cardiology</i> , 2010, 106, 1527-1533.	1.6	45
82	Serial Intravascular Ultrasound Analysis of the Impact of Myocardial Bridge on Neointimal Proliferation After Coronary Stenting in Patients with Acute Myocardial Infarction. <i>Journal of Interventional Cardiology</i> , 2010, 23, 114-122.	1.2	12
83	Clinical and Angiographic Predictors of Short- and Long-Term Ischemic Events in Acute Coronary Syndromes. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 308-316.	3.9	68
84	Response to Letter Regarding Article, "Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications: Assessment From the Acute Catheterization and Urgent Intervention Triage Strategy Trial". <i>Circulation</i> , 2010, 122, .	1.6	2
85	Incidence, Mechanisms, Predictors, and Clinical Impact of Acute and Late Stent Malapposition After Primary Intervention in Patients With Acute Myocardial Infarction. <i>Circulation</i> , 2010, 122, 1077-1084.	1.6	163
86	Prognostic Modeling of Individual Patient Risk and Mortality Impact of Ischemic and Hemorrhagic Complications. <i>Circulation</i> , 2010, 121, 43-51.	1.6	120
87	When Is Door-to-Balloon Time Critical?. <i>Journal of the American College of Cardiology</i> , 2010, 56, 407-413.	2.8	101
88	Selection Criteria for Drug-Eluting Versus Bare-Metal Stents and the Impact of Routine Angiographic Follow-Up. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1597-1604.	2.8	83
89	A Risk Score to Predict Bleeding in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2556-2566.	2.8	590
90	Early Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Drug-Eluting and Bare Metal Stents. <i>Circulation</i> , 2009, 119, 687-698.	1.6	172

#	ARTICLE	IF	CITATIONS
91	Volumetric Intravascular Ultrasound Analysis of Paclitaxel-Eluting and Bare Metal Stents in Acute Myocardial Infarction. <i>Circulation</i> , 2009, 120, 1875-1882.	1.6	51
92	Impact of Gender and Antithrombin Strategy on Early and Late Clinical Outcomes in Patients With Non- σ -ST-Elevation Acute Coronary Syndromes (from the ACUITY Trial). <i>American Journal of Cardiology</i> , 2009, 103, 1196-1203.	1.6	81
93	5-Year Clinical Outcomes After Sirolimus-Eluting Stent Implantation. <i>Journal of the American College of Cardiology</i> , 2009, 54, 894-902.	2.8	142
94	Role of Clopidogrel Loading Dose in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Angioplasty. <i>Journal of the American College of Cardiology</i> , 2009, 54, 1438-1446.	2.8	147
95	Paclitaxel-Eluting Stents versus Bare-Metal Stents in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2009, 360, 1946-1959.	27.0	657
96	Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial. <i>Lancet</i> , The, 2009, 374, 1149-1159.	13.7	368
97	Effectiveness of Drug-Eluting Stent Implantation for Patients With Unprotected Left Main Coronary Artery Stenosis. <i>American Journal of Cardiology</i> , 2008, 101, 801-806.	1.6	59
98	The Harmonizing Outcomes with RevascularizatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: Study design and rationale. <i>American Heart Journal</i> , 2008, 156, 44-56.	2.7	152
99	Bivalirudin during Primary PCI in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2218-2230.	27.0	1,693
100	Associations of Plasma Natriuretic Peptide, Adrenomedullin, and Homocysteine Levels With Alterations in Arterial Stiffness. <i>Circulation</i> , 2007, 115, 3079-3085.	1.6	52
101	Pulse Pressure and Risk of New-Onset Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 709.	7.4	300
102	Phenotype-genotype association grid: a convenient method for summarizing multiple association analyses. <i>BMC Genetics</i> , 2006, 7, 30.	2.7	3
103	Relations of Inflammation and Novel Risk Factors to Valvular Calcification. <i>American Journal of Cardiology</i> , 2006, 97, 1502-1505.	1.6	60
104	Cross-Sectional Association of Kidney Function with Valvular and Annular Calcification. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 521-527.	6.1	155
105	Cross-Sectional Relations of Peripheral Microvascular Function, Cardiovascular Disease Risk Factors, and Aortic Stiffness. <i>Circulation</i> , 2005, 112, 3722-3728.	1.6	259
106	Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. <i>Circulation</i> , 2005, 112, 3066-3072.	1.6	1,650
107	Parental Atrial Fibrillation as a Risk Factor for Atrial Fibrillation in Offspring. <i>JAMA - Journal of the American Medical Association</i> , 2004, 291, 2851.	7.4	521
108	Obesity and the Risk of New-Onset Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2004, 292, 2471.	7.4	1,188

#	ARTICLE	IF	CITATIONS
109	Sex and Age Differences in Lipoprotein Subclasses Measured by Nuclear Magnetic Resonance Spectroscopy: The Framingham Study. <i>Clinical Chemistry</i> , 2004, 50, 1189-1200.	3.2	259
110	Changes in Arterial Stiffness and Wave Reflection With Advancing Age in Healthy Men and Women. <i>Hypertension</i> , 2004, 43, 1239-1245.	2.7	1,290
111	Local Shear Stress and Brachial Artery Flow-Mediated Dilation. <i>Hypertension</i> , 2004, 44, 134-139.	2.7	361
112	Mitral annular calcification is a predictor for incident atrial fibrillation. <i>Atherosclerosis</i> , 2004, 173, 291-294.	0.8	96
113	Asthma, Wheezing, and Allergies in Russian Schoolchildren in Relation to New Surface Materials in the Home. <i>American Journal of Public Health</i> , 2004, 94, 560-562.	2.7	152
114	Housing Characteristics and Children's Respiratory Health in the Russian Federation. <i>American Journal of Public Health</i> , 2004, 94, 657-662.	2.7	79
115	Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. <i>American Journal of Medicine</i> , 2003, 115, 429-435.	1.5	348
116	Impact of Glucose Intolerance and Insulin Resistance on Cardiac Structure and Function. <i>Circulation</i> , 2003, 107, 448-454.	1.6	451
117	Mitral Annular Calcification Predicts Cardiovascular Morbidity and Mortality. <i>Circulation</i> , 2003, 107, 1492-1496.	1.6	397
118	Incorporation of historical controls using semiparametric mixed models. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2001, 50, 31-42.	1.0	30
119	Flexible estimates of tumour incidence for intermediately lethal tumours in a typical long-term animal bioassay. <i>Journal of the Royal Statistical Society Series C: Applied Statistics</i> , 2001, 50, 171-185.	1.0	1